Neogenomics, Inc.
NEO
$16.22
$0.382.40%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 104.96% | 34.01% | 35.52% | -53.28% | -141.88% |
| Total Depreciation and Amortization | -4.28% | -7.42% | -9.86% | -8.61% | -4.62% |
| Total Amortization of Deferred Charges | -37.31% | -- | -47.68% | -47.81% | 69.60% |
| Total Other Non-Cash Items | -105.70% | -10.31% | -1.83% | 80.76% | 182.76% |
| Change in Net Operating Assets | -83.64% | 36.51% | -284.28% | 91.01% | 579.25% |
| Cash from Operations | -1.82% | 67.87% | -86.30% | -3.92% | 46.34% |
| Capital Expenditure | -29.99% | -11.11% | 32.14% | 23.01% | 51.65% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -103.33% | -- | -108.15% | 16.71% | -85.29% |
| Cash from Investing | 10.68% | -240.45% | -15.33% | 92.12% | -227.36% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -31.28% | -- | -- | -- | -- |
| Issuance of Common Stock | 117.47% | -- | -87.83% | -54.89% | -29.25% |
| Repurchase of Common Stock | -997.31% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 93.95% | -135.62% | -37.26% | -35.00% | -10,396.69% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 99.68% | 35.27% | -189.62% | 36.01% | -926.34% |